CN1332666C - 一种抗老年痴呆症复合制剂 - Google Patents
一种抗老年痴呆症复合制剂 Download PDFInfo
- Publication number
- CN1332666C CN1332666C CNB2004100427747A CN200410042774A CN1332666C CN 1332666 C CN1332666 C CN 1332666C CN B2004100427747 A CNB2004100427747 A CN B2004100427747A CN 200410042774 A CN200410042774 A CN 200410042774A CN 1332666 C CN1332666 C CN 1332666C
- Authority
- CN
- China
- Prior art keywords
- senile dementia
- amyloid
- nicotine
- compound formulation
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 65
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 65
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 46
- 229960002715 nicotine Drugs 0.000 claims abstract description 46
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 43
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 16
- 244000068988 Glycine max Species 0.000 claims abstract description 16
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 16
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 229940046009 vitamin E Drugs 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 239000000654 additive Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 68
- 238000009472 formulation Methods 0.000 claims description 48
- 239000002775 capsule Substances 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 60
- 102000054727 Serum Amyloid A Human genes 0.000 description 52
- 108700028909 Serum Amyloid A Proteins 0.000 description 52
- 230000000971 hippocampal effect Effects 0.000 description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
- 238000011830 transgenic mouse model Methods 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 102000003952 Caspase 3 Human genes 0.000 description 8
- 108090000397 Caspase 3 Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- 230000006933 amyloid-beta aggregation Effects 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000002385 metal-ion deposition Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 2
- 230000001201 calcium accumulation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AQCRXZYYMOXFAN-UHFFFAOYSA-N 2-(1-methyl-2-pyrrolidinyl)-pyridine Chemical compound CN1CCCC1C1=CC=CC=N1 AQCRXZYYMOXFAN-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001163 intracellular calcium accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100427747A CN1332666C (zh) | 2004-05-26 | 2004-05-26 | 一种抗老年痴呆症复合制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100427747A CN1332666C (zh) | 2004-05-26 | 2004-05-26 | 一种抗老年痴呆症复合制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1704055A CN1704055A (zh) | 2005-12-07 |
CN1332666C true CN1332666C (zh) | 2007-08-22 |
Family
ID=35575775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100427747A Expired - Fee Related CN1332666C (zh) | 2004-05-26 | 2004-05-26 | 一种抗老年痴呆症复合制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1332666C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101933968A (zh) * | 2010-09-10 | 2011-01-05 | 重庆希尔安药业有限公司 | 一种具有抗氧化、延缓衰老功能的药物组合物及其制备方法 |
CN113648286A (zh) * | 2020-05-12 | 2021-11-16 | 辽宁医学诊疗科技研发中心有限公司 | 一种具有抗老年痴呆功效的制剂产品 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127989A (zh) * | 1993-07-26 | 1996-07-31 | 法马西亚公司 | 改进的尼古丁锭剂和戒烟治疗的方法 |
CN1275569A (zh) * | 1999-06-01 | 2000-12-06 | 淄博华航药业有限公司 | 维生素c生产新工艺 |
CN1318064A (zh) * | 1998-09-18 | 2001-10-17 | 阿方蒂动物营养素股份有限公司 | 维生素e的制备方法 |
-
2004
- 2004-05-26 CN CNB2004100427747A patent/CN1332666C/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127989A (zh) * | 1993-07-26 | 1996-07-31 | 法马西亚公司 | 改进的尼古丁锭剂和戒烟治疗的方法 |
CN1318064A (zh) * | 1998-09-18 | 2001-10-17 | 阿方蒂动物营养素股份有限公司 | 维生素e的制备方法 |
CN1275569A (zh) * | 1999-06-01 | 2000-12-06 | 淄博华航药业有限公司 | 维生素c生产新工艺 |
Non-Patent Citations (1)
Title |
---|
阿尔茨海默病实验干预研究进展 杨勇,洪玉,马龙,等,中国老年学杂志,第24卷第3期 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1704055A (zh) | 2005-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wong et al. | Relationships between mitochondrial dysfunction and neurotransmission failure in Alzheimer’s disease | |
Nguyen et al. | Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders | |
Baldessarini | Fluoxetine and side effects | |
US20100048713A1 (en) | Compounds acting on the serotonin transporter | |
KR20130043217A (ko) | 덱스트로메토르판 및 퀴니딘을 포함하는 신경계 장애의 치료를 위한 약학적 조성물 | |
JP2009149524A (ja) | アルツハイマー病の予防・治療剤 | |
Devoize et al. | Influence of naloxone on antidepressant drug effects in the forced swimming test in mice | |
CN110167562A (zh) | Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用 | |
Wood et al. | Drug-induced psychosis and depression in the elderly | |
CA2986431C (en) | Galantamine clearance of amyloid.beta. | |
AHMED et al. | Potential role of some nutraceuticals in the regression of Alzheimer’s disease in an experimental animal model | |
Omoruyi et al. | In vitro neuroprotective potential of Clivia miniata and Nerine humilis (Amaryllidaceae) in MPP+-induced neuronal toxicity in SH-SY5Y neuroblastoma cells | |
Leinonen et al. | Long‐term efficacy and safety of milnacipran compared to clomipramine in patients with major depression | |
Wang et al. | Acetylshikonin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant oral cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway | |
CN1332666C (zh) | 一种抗老年痴呆症复合制剂 | |
Qi et al. | Alpinia oxyphylla–Schisandra chinensis Herb Pair Alleviates Amyloid-β Induced Cognitive Deficits via PI3K/Akt/Gsk-3β/CREB Pathway | |
CN1332667C (zh) | 一种抗帕金森症(pd)复合制剂 | |
JP2011037722A (ja) | 小胞体ストレスによる神経細胞死の予防又は抑制剤 | |
JP2019517550A (ja) | アンドログラホリドが進化型の多発性硬化症を処置する | |
Govindarajulu et al. | Reserpine-Induced Depression and other neurotoxicity: A monoaminergic hypothesis | |
Kostowski et al. | II. The effects of some hallucinogens on aggressiveness of mice and rats | |
Chhimpa et al. | Pharmacotherapy of Alzheimer’s disease | |
JP2006206584A (ja) | アミロイドβ蛋白の凝集抑制剤、凝集アミロイドβ蛋白の分解剤、抗痴呆薬および抗痴呆性食品 | |
Giri et al. | Combinatorial therapy in Alzheimer's disease | |
Lei et al. | Gypenoside IX restores Akt/GSK-3β pathway and alleviates Alzheimer’s disease-like neuropathology and cognitive deficits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20051207 Assignee: XUCHANG BAIYAOCAOYUAN BIOLOGICAL SCIENCE & TECHNOLOGY CO., LTD. Assignor: Institute of Biophysics, Chinese Academy of Sciences Contract record no.: 2014990000368 Denomination of invention: Compound preparation for resisting senile dementia Granted publication date: 20070822 License type: Common License Record date: 20140603 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070822 Termination date: 20180526 |
|
CF01 | Termination of patent right due to non-payment of annual fee |